Skip to Content

'
Hagop M. Kantarjian, M. D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Vice President for Global Academic Programs, The University of Texas MD Anderson Cancer Center, Houston, TX
Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Kelcie Margaret Kana - Research Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1983 The University of Texas MD Anderson Cancer Center, Houston, TX, Medical Oncology Subspecialty, Hematology/Oncology
1981 American University of Beirut, Beirut, Lebanon, Internal Medicine, Internal Medicine
1979 American University of Beirut, Beirut, Lebanon, MD, Medicine
1975 American University of Beirut, Beirut, Lebanon, BS, Science
1972 American University of Beirut, Beirut, Lebanon, BaccalaureateII

Board Certifications

1990 American Board of Hematology Certification
1985 American Board of Medical Oncology Certification
1983 American Board of Internal Medicine Certification

Honors and Awards

2012 37th Jeffrey A Gottlieb Memorial Award
2010 Ben Qurrah Award
2009-2010 Best Doctors in America 2009-2010, Best Doctors
2008 The Division of Cancer Medicine, MD Anderson Cancer Center "John Mendelsohn Lifetime Scientific Achievement Award", MD Anderson Cancer Center
2008 The Division of Cancer Medicine, MD Anderson Cancer Center 'Waun Ki Hong Award for Excellence in Team Science", MD Anderson Cancer Center
2005 America’s Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical
2004 America’s Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical
2003 America’s Top Doctors, Southwestern Region Top Hematologist, Castle Connolly Medical
1999 Faculty Achievement Award for Clinical Research, UT M.D. Anderson Cancer Center
1998 Kelcie Margaret Kana Research Chair, UT M.D. Anderson Cancer Center
1997 First Emil J Freireich Award for Outstanding Clinical Research, UT M.D. Anderson Cancer Center
1997 Outstanding Service to Mankind Award, Leukemia Society of America
1989-1994 Scholar, Leukemia Society of America
1985-1987 Special Fellow, Leukemia Society of America
1984 Fellow, Leukemia Society of America
1983 Fellow Research Award, UT M.D. Anderson Cancer Center
1982 Fellow Research Award, UT M.D. Anderson Cancer Center
1979 Alpha Omega Alpha Honor Medical Society, American University of Beirut Chapter,Beirut, Lebanon
1979 Penrose Award
1976 Lange Award

Professional Memberships

American Association for Cancer Research
Member, 1/1990-present
American Association for the Advancement of Sciences
Member, 1/1991-present
American Medical Association
Member, 1/1985-present
American Society for Clinical Oncology
member, 1/1995-present
American Society for Hematology
member, 1/1992-present
Association of American Physicians
Member, 2004
International Association for Comparative Research on Leukemia and Related Diseases, Mannheim, Germany
Member of the Nominating Committee, 2/2010-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM. Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial. J Clin Oncol 30(20):2492-9, 7/10/2012. e-Pub 5/14/2012. PMID: 22585697.
2. Liu X, Kantarjian H, Plunkett W. Sapacitabine for cancer. Expert Opin Investig Drugs 21(4):541-55, 4/2012. e-Pub 2/2012. PMCID: PMC3366487.
3. Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 118(3):722-728, 2/1/2012. e-Pub 7/12/2011. PMID: 21751197.
4. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118(2):418-427, 1/2012. e-Pub 6/2011. PMID: 21717444.
5. Tong WG, Estrov Z, Wang Y, O'Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs 29(6):1206-1212, 12/2011. e-Pub 6/2010. PMID: 20533075.
6. Abdel-Karim I, Plunkett WK, O'Brien S, Giles F, Thomas D, Faderl S, Ravandi F, Rios MB, Du M, Schneck KB, Chen VJ, Lin BK, Nicol SJ, Kantarjian HM. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs 29(2):323-331, 4/2011. e-Pub 1/2010. PMID: 20091088.
7. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, Albitar M. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res 35(4):526-33, 4/2011. e-Pub 10/2010. PMID: 20951430.
8. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-3024, 3/17/2011. e-Pub 1/18/2011. PMID: 21245487.
9. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 117(12):3294-3301, 3/24/2011. e-Pub 1/26/2011. PMCID: PMC3069671.
10. Jabbour E, Kantarjian H, Ravandi F, Garcia-Manero G, Estrov Z, Verstovsek S, O'Brien S, Faderl S, Thomas DA, Wright JJ, Cortes J. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 117(6):1236-44, 3/2011. e-Pub 10/2010. PMID: 20960519.
11. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, Hagemeister F, Medeiros J, Cortes J, Kantarjian H. Burkitt Lymphoma and Atypical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Different Diseases? Curr Hematol Malig Rep 6(1):58-66, 3/2011. e-Pub 12/2010. PMID: 21191675.
12. Jabbour E, Cortes J, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 117(5):897-906, 3/2011. e-Pub 10/2010. PMID: 20945321.
13. Santos FP, Alvarado Y, Kantarjian H, Verma D, O'Brien S, Mattiuzzi G, Ravandi F, Borthakur G, Cortes J. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 117(5):982-91, 3/2011. e-Pub 10/2010. PMID: 20960502.
14. Cortes J, Quintás-Cardama A, Kantarjian HM. Monitoring molecular response in chronic myeloid leukemia. Cancer 117(6):1113-22, 3/2011. e-Pub 10/2010. PMID: 20960522.
15. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-3647, 3/2011. e-Pub 12/2010. PMID: 21156844.
16. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 117(5):992-1000, 3/2011. e-Pub 10/2010. PMID: 20945323.
17. Santos FP, Kantarjian H, Garcia-Manero G, Ravandi F. The Search for Better Prognostic Models in Myelodysplastic Syndromes. Curr Hematol Malig Rep 6(1):13-21, 3/2011. e-Pub 12/2010. PMID: 21136214.
18. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 117(4):662-76, 2/15/2011. e-Pub 10/4/2010. PMID: 20922795.
19. Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-Line and Salvage Therapies With Tyrosine Kinase Inhibitors and Other Treatments in Chronic Myeloid Leukemia. J Clin Oncol 29(5):524-531, 2/10/2011. e-Pub 1/10/2011. PMID: 21220597.
20. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 117(5):1662-9, 2/2011. e-Pub 11/2010. PMID: 21115978.
21. Kantarjian H, Schiffer C, Burnett A. Hematologic Malignancies: Where Do We Stand in 2011? J Clin Oncol 29(5):473-4, 2/2011. e-Pub 1/2011. PMID: 21220610.
22. Cortes J, Quintás-Cardama A, Jones D, Ravandi F, Garcia-Manero G, Verstovsek S, Koller C, Hiteshew J, Shan J, O'Brien S, Kantarjian H. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer 117(3):572-80, 2/2011. e-Pub 9/2010. PMID: 20886606.
23. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10(2):127-133, 2/2011. PMID: 21283107.
24. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-1827, 2/2011. e-Pub 10/2010. PMID: 21030554.
25. Carter BZ, Qiu YH, Zhang N, Coombes KR, Mak DH, Thomas DA, Ravandi F, Kantarjian HM, Koller E, Andreeff M, Kornblau SM. Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML. Blood 117(3):780-7, 1/20/2011. e-Pub 11/1/2010. PMCID: PMC3035072.
26. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117(3):920-7, 1/20/2011. e-Pub 11/9/2010. PMID: 21063027.
27. Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer 117(2):327-35, 1/2011. e-Pub 9/2010. PMID: 20845478.
28. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4):1141-5, 1/2011. e-Pub 11/2010. PMID: 21098399.
29. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, Garcia-Manero G, Cortes J, Ravandi F. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 117(1):110-5, 1/2011. e-Pub 8/2010. PMID: 20803607.
30. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ, Faderl S, Verstovsek S, Mathews S, Andreeff M, Cortes JE. Phase 1 Study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96(1):62-8, 1/2011. e-Pub 10/2010. PMCID: PMC3012766.
31. Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M. XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34(+)38 (-) cells in a phase 1/2 study of patients with relapsed/refractory AML. Apoptosis 16(1):67-74, 1/2011. e-Pub 10/2010. PMID: 20938744.
32. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 28(35):e732-e734, 12/10/2010. e-Pub 9/7/2010. PMID: 20823404.
33. Santos FP, Kantarjian H, Cortes J, Quintas-Cardama A. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. Curr Opin Investig Drugs 11(12):1450-1465, 12/2010. PMID: 21154127.
34. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, Santos FP, Shan J, Brandt M, de Lima M, Pierce S, Kantarjian H. Characteristics and outcome of patients with acute myeloid leukemia refractory to one cycle of high dose cytarabine-based induction chemotherapy. Blood 116(26):5818-23; quiz 6153, 12/2010. e-Pub 10/2010. PMID: 20923968.
35. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood 116(23):5074-5, 12/2010. PMID: 21127188.
36. Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 116(24):5659-66, 12/2010. PMID: 21218459.
37. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, Pierce S, Shan J, Cortes J, O'Brien S. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116(24):5568-74, 12/2010. e-Pub 8/2010. PMID: 20737576.
38. Fullmer A, Kantarjian H, Cortes J, Jabbour E. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia. Expert Opin Pharmacother 11(18):3065-3072, 12/2010. e-Pub 11/2010. PMID: 21073351.
39. Saglio G, Kantarjian H, Holyoake T, Ranganathan A, Cortés JE. Proceedings of the third global workshop on chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 10(6):443-51, 12/2010. PMID: 21156461.
40. Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Mod Pathol 23(11):1524-34, 11/2010. e-Pub 8/20/2010. PMID: 20729815.
41. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 11/2010. e-Pub 7/2010. PMID: 20668231.
42. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer 116(22):5272, 11/2010. e-Pub 7/2010. PMID: 20665501.
43. Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 117(9). e-Pub 11/2010. PMID: 21117167.
44. Santos FP, Jones D, Qiao W, Cortes JE, Ravandi F, Estey EE, Verma D, Kantarjian H, Borthakur G. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 117(10). e-Pub 11/2010. PMID: 21117230.
45. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer 116(19):4580-9, 10/2010. e-Pub 6/2010. PMID: 20572037.
46. Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol 47(4):344-53, 10/2010. PMID: 20875551.
47. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res 34(10):1320-4, 10/2010. e-Pub 4/2010. PMID: 20362333.
48. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin JL, Berger DP. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 116(17):3163-3170, 10/2010. e-Pub 7/2010. PMID: 20631375.
49. Quintás-Cardama A, Kantarjian H, Cortes J. Third-generation tyrosine kinase inhibitors and beyond. Semin Hematol 47(4):371-80, 10/2010. PMID: 20875554.
50. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-2077, 9/23/2010. e-Pub 5/13/2010. PMID: 20466853.
51. Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the anti-leukemia agent, CNDAC. Blood 116(10):1737-46, 9/9/2010. e-Pub 5/17/2010. PMCID: PMC2947394.
52. Agrawal M, Garg RJ, Kantarjian H, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep 12(5):302-13, 9/2010. PMID: 20640942.
53. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 116(17):4063-8, 9/2010. PMID: 20564156.
54. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363(12):1117-27, 9/2010. PMID: 20843246.
55. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia. J Clin Oncol 28(24):3880-3889, 8/20/2010. e-Pub 7/26/2010. PMCID: PMC2940403.
56. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ. Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 116(15):3750, 8/1/2010. PMID: 20564160.
57. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116(16):3830-4, 8/15/2010. PMID: 20564137.
58. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116(6):886-892, 8/12/2010. e-Pub 4/28/2010. PMCID: PMC2924226.
59. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, Winton E, Verstovsek S. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk 10(4):285-9, 8/1/2010. PMID: 20709666.
60. Apostolidou E, Kantarjian H, Thomas D, Burger I, Borthakur G, Verstovsek S. Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Clin Lymphoma Myeloma Leuk 10(4):281-4, 8/1/2010. PMID: 20709665.
61. Velev N, Cortes J, Champlin R, Jones D, Rondon G, Giralt S, Borthakur G, Kantarjian HM, De Lima M. Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors with BCR-ABL Kinase Domain Mutation T315I. Cancer 116(15):3631-7, 8/1/2010. PMID: 20564073.
62. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 150(3):303-12, 8/2010. e-Pub 6/10/2010. PMID: 20553275.
63. Bashir Q, De Lima MJ, McMannis JD, Garcia-Manero G, Shpall E, Kantarjian H, Cortes JE, O'Brien SM, Jones D, Qazilbash M, Wei W, Giralt SA, Champlin RE, Hosing C. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy. Leuk Lymphoma 51(8):1478-84, 8/2010. e-Pub 7/27/2010. PMID: 20658954.
64. Golemovic M, Quintás-Cardama A, Manshouri T, Orsolic N, Duzkale H, Johansen M, Freireich EJ, Kantarjian H, Zingaro RA, Verstovsek S. MER1, a novel organic arsenic derivative, has potent PML-RARalpha- independent cytotoxic activity against leukemia cells. Invest New Drugs 28(4):402-412, 8/2010. e-Pub 5/26/2009. PMID: 19468689.
65. Bryan J, Jabbour E, Prescott H, Garcia-Manero G, Issa JP, Kantarjian H. Current and future management options for myelodysplastic syndromes. Drugs 70(11):1381-94, 7/30/2010. PMID: 20614946.
66. Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 116(13):3152-9, 7/2010. PMID: 20564631.
67. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 7/2010. e-Pub 5/26/2010. PMID: 20528872.
68. Bryan J, Jabbour E, Prescott H, Kantarjian H. Thrombocytopenia in patients with myelodysplastic syndromes. Semin Hematol 47(3):274-80, 7/2010. PMID: 20620439.
69. Faderl S, Bueso-Ramos C, Liu Z, Pal A, Bornmann W, Ciurea DV, Harris D, Hazan-Halevy I, Kantarjian HM, Estrov Z. Kit inhibitor APcK110 extends survival in an AML xenograft mouse model. Invest New Drugs. e-Pub 6/3/2010. PMID: 20517635.
70. Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome. J Clin Oncol 28(16):2755-60, 6/1/2010. e-Pub 4/26/2010. PMID: 20421540.
71. Kantarjian H, Coutre P, Cortes J, Pinilla-Ibarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 116(11):2665-72, 6/1/2010. e-Pub 3/2010. PMCID: PMC2876208.
72. Verma D, Kantarjian H, Shan J, O'Brien S, Estrov Z, Garcia-Manero G, Koller C, Borthakur G, Cortes J. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 116(11):2673-81, 6/1/2010. PMID: 20499401.
73. Quintas-Cardama A, Kantarjian H, Cortes J. Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia 10(Suppl. 1):S14-S19, 6/2010.
74. Abdool A, Yeh CH, Kantarjian H, O'Brien S, Bruey J, Giles F, Albitar M. Circulating CD33 and its clinical value in acute leukemia. Exp Hematol 38(6):462-71, 6/2010. e-Pub 4/1/2010. PMID: 20362641.
75. Jabbour E, Fullmer A, Cortes J, Kantarjian H. Clinical Algorithms for the treatment of patients with chronic myeloid leukemia: The 2010 perspective. Clinical Lymphoma, Myeloma and Leukemia 10(Suppl. 1):S6-S13, 6/2010. PMID: 20529808.
76. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N Engl J Med 362(24):2260-70, 6/2010. e-Pub 6/2010. PMID: 20525995.
77. Batty GN, Kantarjian H, Issa JP, Jabbour E, Santos FP, McCue D, Garcia-Manero G, Pierce S, O'Brien S, Cortés JE, Ravandi F. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 10(3):205-10, 6/2010. PMCID: PMC3726276.
78. Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 24:1299-1301, 6/2010. e-Pub 6/2010. PMID: 20520639.
79. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251-9, 6/2010. e-Pub 6/2010. PMID: 20525993.
80. Ravandi F, Kantarjian H, Faderl S, Garcia-Manero G, O'Brien S, Koller C, Pierce S, Brandt M, Kennedy D, Cortes J, Beran M. Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse. Leuk Res 34(6):752-6, 6/2010. e-Pub 10/29/2009. PMID: 19878996.
81. Samudio IJ, Duvvuri S, Clise-Dwyer K, Watt JC, Mak D, Kantarjian H, Yang D, Ruvolo V, Borthakur G. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells. Leuk Lymphoma 51(5):911-9, 5/2010. PMID: 20423286.
82. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, Faderl S, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Cause of death in patients with lower risk myelodysplastic syndrome. Cancer 116:2174-2179, 5/2010. e-Pub 2/2010. PMID: 20162709.
83. Jabbour E, Thomas D, Cortes J, Kantarjian HM, O'Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer 116:2290-300, 5/2010. e-Pub 3/2010. PMID: 20209620.
84. Sampat K, Rossi A, Garcia-Gutierrez V, Cortes J, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of pericardial effusions in patients with leukemia. Cancer 116:2366-71, 5/2010. e-Pub 3/2010. PMID: 20209609.
85. Verma D, Kantarjian H, Faderl S, O'Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J, Ravandi F. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma 51(5):778-782, 5/2010. e-Pub 3/2010. PMID: 20196624.
86. Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, Kantarjian H, Andreeff M, Konopleva M. Role of Peroxisome Proliferator-Activated Receptor-{gamma} and Its Coactivator DRIP205 in Cellular Responses to CDDO (RTA-401) in Acute Myelogenous Leukemia. Cancer Res 70(12). e-Pub 5/2010. PMID: 20501850.
87. Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol. e-Pub 4/29/2010. PMID: 20456355.
88. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center Study. J Clin Oncol 28(10):1766-71, 4/1/2010. e-Pub 2/16/2010. PMID: 20159819.
89. Quintás-Cardama A, Manshouri T, Estrov Z, Harris D, Zhang Y, Gaikwad A, Kantarjian HM, Verstovsek S. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. e-Pub 4/7/2010. PMID: 20372971.
90. Wang SA, Jabbar K, Lu G, Chen SS, Galili N, Vega F, Jones D, Raza A, Kantarjian H, Garcia-Manero G, McDonnell TJ, Medeiros LJ. 'Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features. Leukemia 24(4):740-7, 4/2010. e-Pub 1/14/2010. PMID: 20072149.
91. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood 115(10):1985-92, 3/11/2010. e-Pub 12/29/2009. PMID: 20040759.
92. Faderl S, O'Brien S, Pui CH, Stock W, Wetzler M, Hoelzer D, Kantarjian HM. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 116(5):1165-76, 3/1/2010. e-Pub 1/2010. PMID: 20101737.
93. Kantarjian HM, Cortes J, La Rosée P, Hochhaus A. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Cancer 116(6):1419-30, 3/15/2010. e-Pub 1/29/2010. PMID: 20120030.
94. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia. J Clin Oncol. e-Pub 3/8/2010. PMID: 20212254.
95. Lee TS, Ma W, Zhang X, Albitar M, Giles F, Cortes J, Kantarjian H. BCR-ABL1INS35 Is Not Uncommon in CML Patients and Is Related to Resistance and Sensitivity to Inhibitors in CML Treatment - Response. Mol Cancer Ther 9(3):772, 3/2010. e-Pub 3/2/2010. PMID: 20197391.
96. Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs 15(1):1-11, 3/2010. e-Pub 1/7/2010. PMID: 20055690.
97. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 24(3):666-8, 3/2010. e-Pub 1/7/2010. PMID: 20054352.
98. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S. Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 51(3):475-480, 3/2010. e-Pub 1/2010. PMID: 20078325.
99. Fullmer A, Kantarjian H, Heiskell T and Jabbour E. The Role of Imatinib in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Clinical Medicine Reviews in Oncology 2010:2, 3/2010.
100. Quintás-Cardama A, Amin HM, Kantarjian H, Verstovsek S. Treatment of aggressive systemic mastocytosis with daclizumab. Leuk Lymphoma 51(3):540-2, 3/2010. e-Pub 12/2009. PMID: 20038223.
101. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes. J Clin Oncol 28(4):605-614, 2/1/2010. e-Pub 12/28/2009. PMCID: PMC2815995.
102. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115(6):1131-1136, 2/11/2010. e-Pub 12/11/2009. PMID: 20008298.
103. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28(4):549-555, 2/1/2010. e-Pub 12/21/2009. PMID: 20026805.
104. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2/2010. e-Pub 11/6/2009. PMID: 19895616.
105. Bruey JM, Kantarjian H, Estrov Z, Zhang Z, Ma W, Albitar F, Abdool A, Thomas D, Yeh C, O'Brien S, Albitar M. Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia. Leuk Res 34(2):173-6, 2/2010. e-Pub 8/12/2009. PMID: 19679351.
106. Tanaka C, Yin OQ, Sethuraman V, Smith T, Wang X, Grouss K, Kantarjian H, Giles F, Ottmann OG, Galitz L, Schran H. Clinical Pharmacokinetics of the BCR-ABL Tyrosine Kinase Inhibitor Nilotinib. Clin Pharmacol Ther 87(2):197-203, 2/2010. e-Pub 11/18/2009. PMID: 19924121.
107. Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis. Leuk Lymphoma 51(2):269-74, 2/2010. e-Pub 12/2009. PMID: 20038218.
108. Jones D, Yao H, Romans A, Dando C, Pierce S, Borthakur G, Hamilton A, Bueso-Ramos C, Ravandi F, Garcia-Manero G, Kantarjian H. Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias. Genes Chromosomes Cancer 49(2):182-91, 2/2010. PMID: 19908318.
109. Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95(2):232-40, 2/2010. PMCID: PMC2817025.
110. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: implications for the treatment of myeloproliferative neoplasms. Blood 115(15). e-Pub 2/2010. PMID: 20130243.
111. Al Ameri A, Koller C, Kantarjian H, Ravandi F, Verstovsek S, Borthakur G, Pierce S, Mattiuzzi G. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 116(1):93-97, 1/1/2010. e-Pub 10/2009. PMID: 19862814.
112. Fullmer A, Cortes J, Kantarjian H, Jabbour E. ASH 2009 meeting report-Top 10 clinically oriented abstracts in acute leukemia. Am J Hematol. e-Pub 1/13/2010. PMID: 20169544.
113. Fullmer A, Cortes J, Kantarjian H, Jabbour E. ASH 2009 meeting report-Top 10 clinically oriented abstracts in chronic myeloid leukemia. Am J Hematol. e-Pub 1/27/2010. PMID: 20201083.
114. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S. Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias. Cancer Res 70(2):447-52, 1/15/2010. e-Pub 1/12/2010. PMCID: PMC2947340.
115. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, Kadia T, Borthakur G, Stigliano D, Shan J, Kantarjian H. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28(3):392-397, 1/20/2010. e-Pub 12/14/2009. PMCID: PMC2815701.
116. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120(1):142-56, 1/4/2010. e-Pub 12/21/2009. PMCID: PMC2799198.
117. Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol 28(2):285-291, 1/10/2010. e-Pub 11/23/2009. PMID: 19933907.
118. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 116(1):424-430, 1/20/2010. e-Pub 12/14/2009. PMID: 20008622.
119. Dimov ND, Medeiros LJ, Kantarjian HM, Cortes JE, Chang KS, Bueso-Ramos CE, Ravandi F. Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients. Cancer 116(2):369-376, 1/15/2010. e-Pub 11/2009. PMID: 19950129.
120. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398-404, 1/20/2010. e-Pub 12/14/2009. PMCID: PMC2815702.
121. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 28(3):437-444, 1/20/2010. e-Pub 12/14/2009. PMID: 20008626.
122. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24(1):6-12, 1/2010. e-Pub 10/1/2009. PMID: 19798095.
123. Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 10(1):9-22, 1/2010. PMID: 20014881.
124. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-8, 1/2010. PMCID: PMC2876330.
125. Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh CH, O'Brien S, Giles F, Bruey JM, Albitar M. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. PLoS One 5(8):e12165, 2010. e-Pub 8/13/2010. PMCID: PMC2921382.
126. Jabbour E, Cortes J, Kantarjian H. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review. Core Evid 4:207-13, 2010. PMCID: PMC2899790.
127. Ma W, Kantarjian H, Zhang K, Zhang X, Wang X, Chen C, Donahue AC, Zhang Z, Yeh CH, O'Brien S, Garcia-Manero G, Caporaso N, Landgren O, Albitar M. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet 11:163, 2010. e-Pub 11/16/2010. PMCID: PMC2992491.

Editorials

1. Kantarjian H, O'Brien S. Questions Regarding Frontline Therapy of Acute Myeloid Leukemia. Cancer 116(21):4896-4901, 11/1/2010. PMID: 20623787.

Abstracts

1. 15th Congress of the European Haematology Association. 1 abstract. Please refer to. Haematologica 95(S1), 2010.
2. ASCO 46th Annual Meeting. 28 abstracts. Please refer to. JCO 28(15S), 2010.

Book Chapters

1. Jabbour E, Kantarjian H, Cortes J. Chronoic Myeloid Leukemia. In: Management of Hematologic Malignancies. January 2011, 1st. Ed(s) O'Brien S, Vose J, Kantarjian H. Cambridge University Press: New York, 68-80, 2011.
2. Faderl S, Garcia-Manero G, Kantarjian H. Myelodysplastic Syndromes (MDS). In: Management of Hematologic Malignancies. January 2011, 1st. Ed(s) O'Brien S, Vose J, Kantarjian H. Cambridge University Press: New York, 103-115, 2011.
3. Faderl S, Pui C, O'Brien S, Kantarjian H. Acute Lymphoblastic Leukemia. In: Cancer Medicine, 8th. Ed(s) Hong W, Bast R, Hait W, Kufe D, Pollock R, Weichselbaum R, Holland J, Frei E. People's Medical Publishing House-USA: Shelton, Connecticut, 1591-1603, 2010.
4. Cortes J, Silver R, Kantarjian H. Chronic Myeloid Leukemia. In: Cancer Medicine, 8th. Ed(s) Hong W, Bast R, Hait W, Kufe D, Pollack R, Weichselbaum R, Holland J, Frei E. People's Medical Publishing House-USA: Shelton, Connecticut, 1582-1590, 2010.

Books (edited and written)

1. Jabbour E, Kantarjian H, Cortes J, O'Brien S, Faderl S. Ed(s) Susan O'Brien, Julie M. Vose and Hagop Kantarjian. Management of Hematologic Malignancies. January 2011, 1st. Cambridge University Press: New York, 2011.
2. Zeidan A, Wetzler M, Fletcher A, Whittle A, Bowen D, Koeppen H, Bueso-Ramos C, Konoplev S, Albitar M, Schafer E, Small D. Ed(s) Faderl S, Kantarjian H. Leukemias: Principles and Practice of Therapy, 1st. Wiley-Blackwell: West Sussex, UK, 2010.

Letters to the Editor

1. Jones D, Chen SS, Jabbour E, Rios MB, Kantarjian H, Cortes J. Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects. Blood 115(26):5428, 7/1/2010. PMID: 20595523.

Grant & Contract Support

Title: SPORE in Leukemia Project 1: Epigenetics and Epigenetic Therapy in AML
Funding Source: NIH/NCI
Role: Program Leader
Duration: 9/1/2013 - 8/31/2018
 
Title: SPORE in Leukemia Core A: Administration
Funding Source: NIH/NCI
Role: Core Leader
Duration: 9/1/2013 - 8/31/2018
 
Title: SPORE in Leukemia Developmental Research Program
Funding Source: NIH/NCI
Role: Program Leader
Duration: 9/1/2013 - 8/31/2018
 
Title: SPORE in Leukemia Career Development Program (CDP)
Funding Source: NIH/NCI
Role: Program Leader
Duration: 9/1/2013 - 8/31/2018
 
Title: Cancer Center Support Grant: Hematologic Malignancies Program
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: Ronald dePinho, M.D.
Duration: 7/1/2013 - 6/30/2018
 
Title: The Therapy of CML: Project 1: Improving Cytogenetic and Molecular Complete Responses Using High Dose Imatinib Meyslate (Gleevec; ST1571) with or without PEG-Interferon Alpha 2B and GM-CSF
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Richard Champlin, M.D.
Duration: 7/1/2010 - 6/30/2015
 
Title: The Therapy of CML Core A: Administrative Core
Funding Source: NIH/NCI
Role: Co-Program Leader
Principal Investigator: Richard Champlin, M.D.
Duration: 7/1/2010 - 6/30/2015
 
Title: Therapy of AML: Project 4: Clinical Trials in AML
Funding Source: NIH/NCI
Role: Co-Project Leader
Principal Investigator: Michael Andreeff, M.D., Ph.D.
Duration: 9/20/2007 - 8/31/2014
 
Title: Randomized study of combined epigenetic therapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Jean-Pierre Issa, M.D.
Duration: 9/1/2007 - 7/31/2012
 
Title: Full Member Application Affiliated with SWOG
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Edward Kim, M.D.
Duration: 7/26/2004 - 12/31/2015
 
Title: Research Training in Academic Medical Oncology
Funding Source: NIH/NCI
Role: Mentor
Principal Investigator: Waun K. Hong, M.D.
Duration: 9/30/1994 - 4/30/2015
 
Title: Phase I Studies of Targeted Anti-Cancer Therapies; Clinical Core
Funding Source: NIH/NCI
Role: Consultant
Principal Investigator: Razelle Kurzrock, M.D.
Duration: 3/1/1994 - 2/28/2013

Last updated: 7/31/2014